BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court
路透社2026/10/07 13:31October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)
October 7 - ** Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24
** Halozyme stated it has obtained an injunction (link) from a Dutch court prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets
** The court ruled that Merck infringed Halozyme's EP622 patent and rejected Merck's claim that the patent was invalid
** Halozyme noted that patients can still access the intravenous form of Keytruda, which is not affected by the injunction
** As of the close of the previous trading session, HALO is up 62% year-to-date
(To assist non-native English speakers, Reuters provides automated translations of its reports in several other languages. Automated translation may contain errors or lack the necessary context; Reuters does not guarantee the accuracy of automated translation and provides it solely for the convenience of readers. Reuters assumes no responsibility for any harm or losses arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
GLOBALFOUNDRIES Director Ganesh Moorthy Reports $93,687.50 Share Acquisition
Crypto prices
More
